Risk Stratification and Interventional Cardiology: Robert L. Frye Lecture

Mayo Clinic Proceedings

Volumn 78, Issue 12, 2003, Pages 1507-1518

  Holmes Jr , David R ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM;

ACUTE KIDNEY FAILURE; CARDIOLOGY; CARDIOVASCULAR RISK; CORONARY ARTERY OBSTRUCTION; DOCTOR PATIENT RELATION; FAMILY COUNSELING; HUMAN; MORTALITY; PATIENT CARE; PATIENT COUNSELING; PRACTICE GUIDELINE; PREDICTION; RESTENOSIS; REVIEW; STATISTICAL ANALYSIS; SURGICAL RISK; SURGICAL TECHNIQUE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; TREATMENT PLANNING; UNITED STATES; VASCULAR RESISTANCE;

EID: 0345293095     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/78.12.1507     Document Type: Article

References (72)

1. Gruntzig A. Transluminal dilatation of coronary-artery stenosis [letter]. Lancet. 1978;1:263.
2. King SB III, Schlumpf M. Ten-year completed follow-up of percutaneous transluminal coronary angioplasty: the early Zurich experience. J Am Coll Cardiol. 1993;22:353-360.
3. Meier B. The first patient to undergo coronary angioplasty-23-year follow-up [letter]. N Engl J Med. 2001;344:144-145.
4. Willman VL, Bulkley B, Gruntzig A, et al. Proceedings of the Workshop on Percutaneous Transluminal Coronary Angioplasty: June 15-16, 1979. Bethesda, Md: US Dept of Health, Education, and Welfare, Public Health Service, National Institutes of Health; 1980:9-15. DHEW publication no. (NIH) 80-2030.
5. Holmes DR Jr, Holubkov R, Vlietstra RE, et al, Co-Investigators of the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Comparison of complications during percutaneous transluminal coronary angioplasty from 1977 to 1981 and from 1985 to 1986: the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. J Am Coll Cardiol. 1988;12:1149-1155.
6. Sinclair IN, McCabe CH, Sipperly ME, Baim DS. Predictors, therapeutic options and long-term outcome of abrupt reclosure. Am J Cardiol. 1988;61:61G-66G.
7. Simpfendorfer C, Belardi J, Bellamy G, Galan K, Franco I, Hollman J. Frequency, management and follow-up of patients with acute coronary occlusions after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1987;59:267-269.
8. Kuntz RE, Piana R, Pomerantz RM, et al. Changing incidence and management of abrupt closure following coronary intervention in the new device era. Cathet Cardiovasc Diagn. 1992;27:183-190.
9. Mabin TA, Holmes DR Jr, Smith HC, et al. Intracoronary thrombus: role in coronary occlusion complicating percutaneous transluminal coronary angioplasty. J Am Coll Cardiol. 1985;5:198-202.
10. Sugrue DD, Holmes DR Jr, Smith HC, et al. Coronary artery thrombus as a risk factor for acute vessel occlusion during percutaneous transluminal coronary angioplasty: improving results. Br Heart J. 1986;56:62-66.
11. Reeder GS, Bryant SC, Suman VJ, Holmes DR Jr. Intracoronary thrombus: still a risk factor for PTCA failure? Cathet Cardiovasc Diagn. 1995;34:191-195.
12. Singh M, Berger PB, Ting HH, et al. Influence of coronary thrombus on outcome of percutaneous coronary angioplasty in the current era (the Mayo Clinic experience). Am J Cardiol. 2001;88:1091-1096.
13. Singh M, Reeder GS, Ohman EM, et al. Does the presence of thrombus seen on a coronary angiogram affect the outcome after percutaneous coronary angioplasty? an Angiographic Trials Pool data experience. J Am Coll Cardiol. 2001;38:624-630.
14. Detre KM, Holmes DR Jr, Holubkov R, et al, Coinvestigators of the National Heart, Lung, and Blood Institute's Percutaneous Transluminal Coronary Angioplasty Registry. Incidence and consequences of periprocedural occlusion: the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation. 1990;82:739-750.
15. de Feyter PJ, van den Brand M, Laarman GJ, et al. Acute coronary artery occlusion during and after percutaneous transluminal coronary angioplasty: frequency, prediction, clinical course, management, and follow-up. Circulation. 1991;83:927-936.
16. Holmes DR Jr, Vlietstra RE, Smith HC, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol. 1984;53:77C-81C.
17. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol. 1991;17:758-769.
18. Faxon DP, ed. Restenosis: A Guide to Therapy. London, England: Martin Dunitz; 2001.
19. Hermans WR, Rensing BJ, Foley DP, et al, Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal coronary Obstruction and Restenosis (MERCATOR) study group. Patient, lesion, and procedural variables as risk factors for luminal re-narrowing after successful coronary angioplasty: a quantitative analysis in 653 patients with 778 lesions. J Cardiovasc Pharmacol. 1993;22(suppl 4):S45-S57.
20. Weintraub WS, Kosinski AS, Brown CL III, King SB III. Can restenosis after coronary angioplasty be predicted from clinical variables? J Am Coll Cardiol. 1993;21:6-14.
21. Mercado N, Boersma E, Wijns W, et al. Clinical and quantitative coronary angiographic predictors of coronary restenosis: a comparative analysis from the balloon-to-stent era. J Am Coll Cardiol. 2001;38:645-652.
22. Kastrati A, Schomig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol. 1997;30:1428-1436.
23. Hausleiter J, Kastrati A, Mehilli J, et al. Predictive factors for early cardiac events and angiographic restenosis after coronary stent placement in small coronary arteries. J Am Coll Cardiol. 2002;40:882-889.
24. Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002;40:2082-2089.
25. Laskey WK, Kimmel S, Krone RJ. Contemporary trends in coronary intervention: a report from the Registry of the Society for Cardiac Angiography and Interventions. Catheter Cardiovasc Interv. 2000;49:19-22.
26. Al Suwaidi J, Berger PB, Holmes DR Jr. Coronary artery stents. JAMA. 2000;284:1828-1836.
27. Rankin JM, Spinelli JJ, Carere RG, et al. Improved clinical outcome after widespread use of coronary-artery stenting in Canada. N Engl J Med. 1999;341:1957-1965.
28. Kimmel SE, Localio AR, Krone RJ, Laskey WK, Registry Committee of the Society for Cardiac Angiography and Interventions. The effects of contemporary use of coronary stents on in-hospital mortality. J Am Coll Cardiol. 2001;37:499-504.
29. Williams DO, Holubkov R, Yeh W, et al, Coinvestigators. Percutaneous coronary intervention in the current era compared with 1985-1986: the National Heart, Lung, and Blood Institute Registries. Circulation. 2000;102:2945-2951.
30. McGrath PD, Malenka DJ, Wennberg DE, et al, Northern New England Cardiovascular Disease Study Group. Changing outcomes in percutaneous coronary interventions: a study of 34,752 procedures in northern New England, 1990 to 1997. J Am Coll Cardiol. 1999;34:674-680.
31. Anderson HV, Shaw RE, Brindis RG, et al, ACC-NCDR. A contemporary overview of percutaneous coronary interventions: the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol. 2002;39:1096-1103.
32. Steinhubl SR, Berger PB, Mann JT III, et al, CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [published correction appears in JAMA. 2003;289:987]. JAMA. 2002;288:2411-2420.
33. Steinhubl SR, Berger PB, Mann JT III, et al, CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial [published correction appears in JAMA. 2003;289:987]. JAMA. 2002;288:2411-2420.
34. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) Study. Circulation. 1999;99:1597-1603.
35. Leon MB, Baim DS, Popma JJ, et al, Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998;339:1665-1671.
36. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334:1084-1089.
37. Topol EJ, Moliterno DJ, Herrmann HC, et al, TARGET Investigators. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med. 2001;344:1888-1894.
38. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
39. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial [published correction appears in Lancet. 2001;357:1370]. Lancet. 2000;356:2037-2044.
40. ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial [published correction appears in Lancet. 2001;357:1370]. Lancet. 2000;356:2037-2044.
41. Holmes DR Jr, Savage M, LaBlanche JM, et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2002;106:1243-1250.
42. Regar E, Serruys PW, Bode C, et al, RAVEL Study Group. Angiographic findings of the multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL): sirolimus-eluting stents inhibit restenosis irrespective of the vessel size. Circulation. 2002;106:1949-1956.
43. Morice MC, Serruys PW, Sousa JE, et al, RAVEL Study Group. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
44. Leon MB, Moses JW, Popma JJ, Kuntz RE, Fitzgerald P, SIRIUS Investigators. SIRIUS: a US, multicenter, randomized, double blind study of the sirolimus-eluting stent in de novo native coronary lesions. N Engl J Med. In press.
45. Orford JL, Lennon R, Melby S, et al. Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry. J Am Coll Cardiol. 2002;40:1567-1572.
46. Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 2001;103:1967-1971.
47. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol. 2002;39:9-14.
48. Berglund U, Richter A. Clopidogrel treatment before percutaneous coronary intervention reduces adverse cardiac events. J Invasive Cardiol. 2002;14:243-246.
49. Seyfarth HJ, Koksch M, Roethig G, et al. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J. 2002;143:118-123.
50. Leon MB, Teirstein PS, Moses JW, et al. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting. N Engl J Med. 2001;344:250-256.
51. Marks DS, Mensah GA, Kennard ED, Detre K, Holmes DR Jr. Race, baseline characteristics, and clinical outcomes after coronary intervention: the New Approaches in Coronary Interventions (NACI) registry. Am Heart J. 2000;140:162-169.
52. Peterson ED, Lansky AJ, Anstrom KJ, et al, National Cardiovascular Network. Evolving trends in interventional device use and outcomes: results from the National Cardiovascular Network Database. Am Heart J. 2000;139:198-207.
53. Seshadri N, Whitlow PL, Acharya N, Houghtaling P, Blackstone EH, Ellis SG. Emergency coronary artery bypass surgery in the contemporary percutaneous coronary intervention era. Circulation. 2002;106:2346-2350.
54. Freeman RV, O'Donnell M, Share D, et al, Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. Am J Cardiol. 2002;90:1068-1073.
55. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med. 1994;331:1416-1420.
56. Stevens MA, McCullough PA, Tobin KJ, et al. A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. J Am Coll Cardiol. 1999;33:403-411.
57. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180-184.
58. Abizaid AS, Clark CE, Mintz GS, et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol. 1999;83:260-263.
59. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older: a prospective study. Arch Intern Med. 1990;150:1237-1242.
60. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259-2264.
61. Ellis SG, Weintraub W, Holmes D, Shaw R, Block PC, King SB III. Relation of operator volume and experience to procedural outcome of percutaneous coronary revascularization at hospitals with high interventional volumes. Circulation. 1997;95:2479-2484.
62. Holmes DR Jr, Berger PB, Garratt KN, et al. Application of the New York State PTCA mortality model in patients undergoing stent implantation. Circulation. 2000;102:517-522.
63. Moscucci M, Kline-Rogers E, Share D, et al, Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Simple bedside additive tool for prediction of in-hospital mortality after percutaneous coronary interventions. Circulation. 2001;104:263-268.
64. O'Connor GT, Malenka DJ, Quinton H, et al, Northern New England Cardiovascular Disease Study Group. Multivariate prediction of in-hospital mortality after percutaneous coronary interventions in 1994-1996. J Am Coll Cardiol. 1999;34:681-691.
65. Rihal CS, Grill DE, Bell MR, Berger PB, Garratt KN, Holmes DR Jr. Prediction of death after percutaneous coronary interventional procedures. Am Heart J. 2000;139:1032-1038.
66. Shaw RE, Anderson HV, Brindis RG, et al, ACC-NCDR. Development of a risk adjustment mortality model using the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR) experience: 1998-2000. J Am Coll Cardiol. 2002;39:1104-1112.
67. Singh M, Lennon RJ, Holmes DR Jr, Bell MR, Rihal CS. Correlates of procedural complications and a simple integer risk score for percutaneous coronary intervention. J Am Coll Cardiol. 2002;40:387-393.
68. Holmes DR, Selzer F, Johnston JM, et al. Modeling and risk prediction in the current era of interventional cardiology: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. Circulation. 2003;107:1871-1876.
69. Hasdai D, Holmes DR Jr, Califf RM, et al, GUSTO-I Investigators. Cardiogenic shock complicating acute myocardial infarction: predictors of death. Am Heart J. 1999;138:21-31.
70. Holmes DR Jr, Bates ER, Kleiman NS, et al, GUSTO-I Investigators. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. J Am Coll Cardiol. 1995;26:668-674.
71. Hochman JS, Sleeper LA, Webb JG, et al, SHOCK Investigators. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med. 1999;341:625-634.
72. Hasdai D, Califf RM, Thompson TD, et al. Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol. 2000;35:136-143.